Plancarte-Sánchez R, Mansilla-Olivares A, De los Reyes-Pacheco VA, Meneses-González F

Language: Spanish
References: 60
Page: 307-318
PDF size: 212.25 Kb.

ABSTRACT

The interest on cannabinoids became evident between the 1940 and 1950 decades. Although the active substance of the plant was not known, a series of compounds with cannabinomimetic activity were synthesized, which were investigated in animals and clinically. The most widely tested was Δ6α, 10α-THC hexyl. Δ6α, 10α-THC dimethylheptyl (DMHP) antiepileptic effects were studied in several children, with positive results being obtained in some cases. DMHP differs from sinhexyl in that its side chain is DMHP instead of n-hexyl. The first cannabinoid isolated from Cannabis sativa was cannabinol, although its structure was correctly characterized several years later. Cannabidiol was isolated some years later and was subsequently characterized by Mechoulam and Shvo. In 2013, the National Academy of Medicine and the Faculty of Medicine of the National Autonomous University of Mexico, through the Seminar of Studies on Entirety, decided to carry out a systematic review on a subject that is both complex and controversial: the relationship between marijuana and health. In recent years, studies have been conducted with cannabis in several diseases: controlled clinical trials on spasticity in multiple sclerosis and spinal cord injury, chronic, essentially neuropathic, pain, movement disorders (Gilles de Latourette, dystonia, levodopa dyskinesia), asthma and glaucoma, as well as non-controlled clinical trials on Alzheimer’s disease, neuroprotection, intractable hiccups, epilepsy, alcohol and opioid dependence and inflammatory processes.

REFERENCES

1. García-Robles J. Antología del vicio. Aventuras y desventuras de la mariguana en México. México: Laberinto; 2016.

2. United Nations Office on Drugs and Crime. 2015 Global estimates of drug use. Suiza: United Nations Office on Drugs and Crime; 2018.

3. Organisation for Economic Co-operation and Development. Data for Chart CO4.3.B. Cannabis use at age 15 by gender, 2013/14. Francia: Organisation for Economic Co-operation and Development; 2019.

4. Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco 2016- 2017. México: Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz/Instituto Nacional de Salud Pública/Comisión Nacional Contra las Adicciones/Secretaría de Salud; 2017.

5. Villatoro-Velázquez JA, Bustos-Gamiño MN, Fregoso-Ito DA, Fleiz-Bautista C, Gutiérrez-López M, Amador-Buenabad N, et al. Contextual factors associated with marijuana use in school population. Salud Mental. 2017;40:93-101.

6. Campbell JM, Thompson R. A dictionary of Assyrian botany. Inglaterra: British Academy; 2014.

7. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78:539-548.

8. Camp WH. The antiquity of hemp as an economic plant. J NY Bot Gard. 2014:110-113.

9. Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci. 2006;27:134-140.

10. Chopra IC, Chopra RN. The use of cannabis drugs in India. Bull Narc. 2013;9:4-29.

11. Durant WJ, Durant A. The story of civilization. Vol I. EE. UU.: Simon and Schuster; 2015.

12. Thompson R. A study of American grown cannabis in comparison with various other sources. Am J Pharm. 2006;84:88-95.

13. Rawlinson G. The Persian wars. EE. UU.: Modern Library; 2015.

14. European Monitoring Centre for Drugs and Drug Addiction. The state of the drugs problem in Europe. Luxemburgo: European Monitoring Centre for Drugs and Drug Addiction; 2011.

15. Decreto por el que se reforman y adicionan diversas disposiciones de la Ley General de Salud y del Código Penal Federal. México: Diario Oficial de la Federación; 2017.

16. Rodríguez-Carranza R. Los productos de cannabis sativa: situación actual y perspectivas en medicina. Salud Mental. 2012;35:247-256.

17. Ware M, Desroches J. Cannabis medicinal y dolor. Pain Clin Update. 2014;22:1-7.

18. Madras BK. Update of cannabis and its medical use. En: Thirty-seventh meeting of the Expert Committee on Drug Dependence. Suiza: World Health Organization; 2015.

19. Brenneisen, R. Chemistry and analysis of phytocannabinoids and other cannabis constituent. En: ElSohly, Mahmoud A editores. Marijuana and the cannabinoids. EE. UU.: Humana Press Inc.; 2007.

20. Rodríguez-Carranza R. Los productos de cannabis sativa: situación actual y perspectivas en medicina. Salud Mental. 2012;35:247-256.

21. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev. 2011;30 599-612.

22. Narváez GO, Guerrero CA. Bases moleculares de la inmunotoxicología experimental de la marihuana. Rev Fac Med Univ Nac Colombia. 2006;54:290-300.

23. Grotenhermen F. Los cannabinoides y el sistema endocannabinoide. Cannabinoids. 2006;1:10-14.

24. Pertwee R. Receptors and pharmacodynamics: natural and synthetic cannabionoids and endocannabinoids. En: Guy GW, Whittle B, Robson P, editores. The medicinal uses of cannabis and cannabinoids. Inglaterra: Pharmaceutical Press; 2004.

25. Gómez-Del Pulgar T, Velasco G, Sánchez C, Haro A, Guzmán M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 2002;363:183-188.

26. Carracedo A, Geelen MJH, Diez M, Hanada K, Guzmán M, Velasco G. Ceramide sensitizes astrocytesto oxidative stress: role of cannabinoids. Biochem J. 2004;380:435-440.

27. McAllister SD, Rigel TC, Horowitz MP, García A, Desprez PY. Cannabidiol as a novel inhibitor gene expression in gressive breast cancer cells. Mol Cancer Ther. 2007;6:2921-2927.

28. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005;68:1484-1495.

29. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Effects of cannabidiol, a nonpsychoactive cannabinoid. J Pharmacol Exp Ther. 2004;308:838-845.

30. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, and potential therapeutic applications. J Med Chem. 2005;48:5059-5087.

31. De la Fuente JR. Botánica, química y farmacología de cannabis sativa. En: Marihuana y salud. Facultad de Ciencias Económicas, Universidad Nacional Autónoma de México, Facultad de Medicina/Academia Nacional de Medicina; 2015.

32. Tamosiunas G, Pagano E, Artagaveytia P. Una introducción al perfil farmacológico y terapéutico de la marihuana. Arch Med Int. 2013; 35:113-116.

33. Ramos-Atance JA, Fernández-Ruiz J. Uso de los cannabinoides a través de la historia. España: Departamento de Bioquímica/Facultad de Medicina/ Universidad Complutense de Madrid; 2015.

34. Araos P, Calado M. Adicción a cannabis: bases neurobiológicas y consecuencias médicas. Rev Esp Drogodependencias. 2014;39:9-29.

35. Lijarcio JI. El consumo de sustancias en la conducción de vehículos, reflexiones y aproximaciones. Rev Esp Drogodependencias. 2015;40 5-11.

36. Whiting PF, Wolff RF, Deshpande S, Di-Nisio M, Duffy S, Hernández AV. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456-2473.

37. Regulación y perspectivas en América Latina sobre el uso del cannabis con fines medicinales. Regulación y perspectivas en América Latina sobre el uso del cannabis con fines medicinales. [Tesis de licenciatura]. Colombia: Universidad Católica de Colombia; 2017.

38. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9:254-264.

39. Ley Federal de Uruguay Capítulo 1 Cannabis psicoactivo de uso médico y no médico, artículo 3º del Decreto Ley 14.294, artículo 5º de la Ley No.19.172. Uruguay: Cámara de Representantes de la República Oriental del Uruguay.

40. A comparison of the world’s first three jurisdictions to legally regulate marijuana: Colorado, Washington and Uruguay. EE. UU.: Drug Policy Alliance; 2014.

41. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med. 2016;48:128-141.

42. Kalant H, Porat-Waller AJ. Clearing the smoke on cannabis. Medical use of cannabis and cannabinoids. An Update. Canadá: Canadian Centre on Substance Abuse; 2016.

43. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3): 270-278.

44. Kalkach-Aparicio M, Cuéllar-Herrera M, Flores-Ramírez EL, Ruiz- Gadea P, Medina-Osti L, Trejo-Martínez D, et al. The use of cannabis as an antiepileptic treatment in Mexico: A review, bioethical analysis, discussion and position of the Hospital General de México Epilepsy Clinic. Rev Med Hosp Gen Mex. 2016;79:68-78.

45. Detyniechi K, Hirsch L. Marijuana use in epilepsy: the myth and the reality. Curr Neurol Neurosci Rep. 2015;15:65.

46. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441.

47. Rog DJ, Nurmikko TJ, Friede T. Randomized controlled trial of cannabis- based medicinal extracts in the treatment of neuropatic, pain due to multiple sclerosis. Ectrims. 2003;9:S25.

48. García-Caldentey J. Neuroprotección por cannabinoides en la enfermedad de Huntington: ensayo clínico Fase II, aleatorizado, doble ciego controlado con placebo y cruzado neuroprotección por cannabinoides en la enfermedad de Huntington [Tesis de doctorado]. España: Universidad de Alcalá; 2013.

49. Fitz Charles MA1, Clauw DJ, Ste-Marie PA, Shir Y. The dilemma of medical marijuana use by rheumatology patients. Arthritis Care Res (Hoboken). 2014;66:797-801.

50. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been… Headache. 2015;55:885-916.

51. Fine PG, Rosenfeld MJ. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med J. 2013;4:e0022.

52. Yunkun D, Lei L, Yuhuai H, Kaiyun F, Jin L. Clinical practice guidelines for management of neuropathic pain. African Med J. 2012;102:312-325.

53. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5 e14433.

54. Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature. 1971;231:260-261.

55. Machado-Rocha FC, Stéfano SC, De-Cássia-Haiek R, Rosa-Oliveira LM, Da Silveira DX. Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17:431-443.

56. Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y. Association cannabis negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken). 2012;64:1202-1208.

57. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis Medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45:50-52.

58. Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, et al. Marijuana Smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis. 2013;57:663-670.

59. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic Pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004;112:299-306.

60. Collado K. Cuestiones de interés en torno a los usos terapéuticos del cannabis. España: Departamento de Farmacología/Centro de Investigación Biomédica en Red de Salud Mental; 2012.